These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 12727037)
1. Clinically important changes in acute pain outcome measures: a validation study. Farrar JT; Berlin JA; Strom BL J Pain Symptom Manage; 2003 May; 25(5):406-11. PubMed ID: 12727037 [TBL] [Abstract][Full Text] [Related]
2. Defining the clinically important difference in pain outcome measures. Farrar JT; Portenoy RK; Berlin JA; Kinman JL; Strom BL Pain; 2000 Dec; 88(3):287-294. PubMed ID: 11068116 [TBL] [Abstract][Full Text] [Related]
3. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Coluzzi PH; Schwartzberg L; Conroy JD; Charapata S; Gay M; Busch MA; Chavez J; Ashley J; Lebo D; McCracken M; Portenoy RK Pain; 2001 Mar; 91(1-2):123-30. PubMed ID: 11240084 [TBL] [Abstract][Full Text] [Related]
4. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176 [TBL] [Abstract][Full Text] [Related]
5. Opioids for the management of breakthrough pain in cancer patients. Zeppetella G; Davies AN Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465 [TBL] [Abstract][Full Text] [Related]
6. Opioids for the management of breakthrough (episodic) pain in cancer patients. Zeppetella G; Ribeiro MD Cochrane Database Syst Rev; 2006 Jan; (1):CD004311. PubMed ID: 16437482 [TBL] [Abstract][Full Text] [Related]
7. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. Farrar JT; Cleary J; Rauck R; Busch M; Nordbrock E J Natl Cancer Inst; 1998 Apr; 90(8):611-6. PubMed ID: 9554444 [TBL] [Abstract][Full Text] [Related]
9. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Mercadante S; Radbruch L; Davies A; Poulain P; Sitte T; Perkins P; Colberg T; Camba MA Curr Med Res Opin; 2009 Nov; 25(11):2805-15. PubMed ID: 19792837 [TBL] [Abstract][Full Text] [Related]
10. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. Christie JM; Simmonds M; Patt R; Coluzzi P; Busch MA; Nordbrock E; Portenoy RK J Clin Oncol; 1998 Oct; 16(10):3238-45. PubMed ID: 9779697 [TBL] [Abstract][Full Text] [Related]
11. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Simpson DM; Messina J; Xie F; Hale M Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282 [TBL] [Abstract][Full Text] [Related]
13. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study. Hanks GW; Nugent M; Higgs CM; Busch MA; Palliat Med; 2004 Dec; 18(8):698-704. PubMed ID: 15623166 [TBL] [Abstract][Full Text] [Related]
14. Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis. Jandhyala R; Fullarton J BMJ Support Palliat Care; 2012 Jun; 2(2):156-62. PubMed ID: 24654058 [TBL] [Abstract][Full Text] [Related]
15. A comparison of change in the 0-10 numeric rating scale to a pain relief scale and global medication performance scale in a short-term clinical trial of breakthrough pain intensity. Farrar JT; Polomano RC; Berlin JA; Strom BL Anesthesiology; 2010 Jun; 112(6):1464-72. PubMed ID: 20463579 [TBL] [Abstract][Full Text] [Related]
16. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer. Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F; Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Rauck R; Reynolds L; Geach J; Bull J; Stearns L; Scherlis M; Parikh N; Dillaha L Curr Med Res Opin; 2012 May; 28(5):859-70. PubMed ID: 22480131 [TBL] [Abstract][Full Text] [Related]
18. A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. Hagen NA; Fisher K; Victorino C; Farrar JT J Palliat Med; 2007 Feb; 10(1):47-55. PubMed ID: 17298253 [TBL] [Abstract][Full Text] [Related]
19. A randomized clinical trial of oral transmucosal fentanyl citrate versus intravenous morphine sulfate for initial control of pain in children with extremity injuries. Mahar PJ; Rana JA; Kennedy CS; Christopher NC Pediatr Emerg Care; 2007 Aug; 23(8):544-8. PubMed ID: 17726413 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of oral transmucosal fentanyl citrate for prehospital pain control on the battlefield. Wedmore IS; Kotwal RS; McManus JG; Pennardt A; Talbot TS; Fowler M; McGhee L J Trauma Acute Care Surg; 2012 Dec; 73(6 Suppl 5):S490-5. PubMed ID: 23192075 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]